XXXX and @entity5616 in long-term treatment of duodenal @entity1066 : a double-blind comparison of length of time in remission.

@entity1 @entity1066 @entity5616 @entity4546
In most @entity1 duodenal @entity1066 is a chronic relapsing disease. If no active maintenance treatment or eradication therapy is given after healing, around 70-100% of @entity1 have a relapse during the first year. We conducted a double-blind multicenter study in 472 @entity1 with duodenal @entity1066 . They were treated with @entity4546 20 mg every morning for four or eight weeks and when healed were randomly allocated to maintenance treatment with either @entity4546 20 mg every morning or @entity5616 150 mg at bedtime for up to six months. The @entity1 were assessed by endoscopy at monthly intervals until healing occurred. Thereafter scheduled endoscopy was carried out after 1, 3, and 6 months of maintenance treatment or immediately in the event of a suspected relapse. Healing status (intention to treat approach) was 87% at four weeks and 93% at eight weeks. At six months the estimated remission rate was 90% for @entity4546 and 82% for @entity5616 (P = 0.03, 95% CI 1-15%). The incidence of adverse events was similar during the two maintenance treatments. Treatment with @entity4546 20 mg every morning maintained significantly more @entity1 in remission than treatment with @entity5616 150 mg at bedtime.
